Intensity-Modulated Radiotherapy (IMRT) — Coverage Criteria for Non‑Medicare Plans
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.69 alerts
Get alerted when Policy CP.MP.69 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity criteria and coding guidance for intensity-modulated radiotherapy (IMRT) for non‑Medicare health plans affiliated with Centene Corporation; governs when IMRT is considered medically necessary for various tumor types and clinical scenarios.
Added note to policy to refer to MC.CP.MP.69 for Medicare criteria and specified 'non‑Medicare' health plans in Policy/Criteria I.
Annual review updated I.G. additions (uterine neoplasms, pancreatic cancer, stage III NSCLC) and removed several prescriptive breast dose-volume subcriteria leaving homogeneity-based criteria.
Policy criteria reorganized to a concise list (I.A–I.E) including age ≤18, medically inoperable patients needing dose escalation, primary bone tumors, re-irradiation, and enumerated cancer site indications.
Medical Necessity Criteria for IMRT
Medically Necessary Indications
IMRT is medically necessary for any of the following (policy I):
Non‑Medicare health plans affiliated with Centene Corporation
Chunk 2
Chunk 2
Chunk 2
Chunk 2
Chunks 2-4
Chunk 2
Chunk 2
Chunks 2-3
Chunk 3
Chunk 3
Chunks 3,11
Chunks 3-4
Chunk 4
Chunk 4
The policy notes several theoretical and practical situations in which IMRT may be less appropriate. These include potential dose inhomogeneity within target volumes, the need for additional time for complex treatment planning and quality assurance (QA) computations, and the possibility of exposing larger volumes of normal tissue to low‑dose radiation. These concerns should be weighed against clinical benefit when selecting IMRT versus alternative techniques.
Coverage and administration of services described in this clinical policy are governed by the member's specific plan documents. Decisions remain subject to the terms, conditions, exclusions and limitations of the applicable evidence of coverage or policy, and to state and federal requirements. When plan or state Medicaid provisions conflict with this policy, those provisions take precedence.
Within the sections provided for this policy, there is no explicit list of services or indications labeled as "not medically necessary." Absence of such a list in these excerpts does not imply universal coverage; clinical determinations and coding guidance still apply.
Coding Guidance and Procedure Codes
| 77301 | Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications. |
| 77338 | Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan. |
| 77385 | Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple. |
| 77386 | Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex. |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session. |
| G6016 | Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session. |
Prior Authorization, Documentation, and Billing Considerations
Use IMRT planning/delivery codes for PA
Prior authorization requests should reference the IMRT planning and delivery procedure codes listed in this policy (e.g., 77301, 77338, 77385, 77386, and the HCPCS G‑codes G6015/G6016 when applicable). Inclusion of these codes in the policy is informational and does not by itself guarantee coverage; follow plan prior authorization procedures.
PA requirements governed by Health Plan
Prior authorization and coverage determinations are governed by the member's Health Plan and applicable state/federal rules; adherence to this clinical policy and any Health Plan-level administrative policies may be required when submitting PA requests.
- Plan-specific prior authorization requirements and administrative policies control final coverage decisions
- State and federal requirements (including Medicaid precedence) apply
No step therapy specified
This clinical policy does not specify any step therapy pathways for IMRT; no step therapy requirements are defined here.
Follow Health Plan administrative submission processes
Follow applicable Health Plan administrative submission processes (e.g., PA forms, timelines, and contact channels) when requesting coverage; this policy does not replace plan-specific administrative instructions.
- Use the Health Plan's PA submission forms and portals
- Comply with any plan-required timelines and documentation checklists
Document clinical indication to match policy criteria
Clinical documentation submitted for PA or claims must support one of the medically necessary indications listed in the policy (for example: patient age <18 with a solid tumor; medically inoperable cancer requiring dose escalation; primary bone tumor; re‑irradiation where cumulative critical structure dose would exceed tolerance; or one of the enumerated site‑specific indications).
- Document age, diagnosis, and tumor site (as applicable)
- For re‑irradiation, document prior dose(s) and estimated cumulative dose to critical structures
Ensure documentation aligns with policy and plan procedures
Ensure submitted documentation and requests align with Health Plan-level administrative policies and the coverage criteria in this clinical policy; follow plan procedures for records, evidentiary requirements, and regulatory obligations.
- Align clinical notes, treatment plans, and dose constraints with policy language
- Follow any Health Plan documentation checklists and legal/regulatory requirements
Verify coding guidance before claim submission
Inclusion or exclusion of procedure codes in this policy does not guarantee payment; providers must verify current professional coding guidance and payer-specific coding rules before claims submission to avoid denials.
- Codes listed are informational and not all‑inclusive
- Reference up-to-date coding manuals and payer guidance prior to billing
Coverage subject to plan terms, exclusions, and state/federal rules
Coverage decisions and benefit administration are subject to the member's coverage documents (e.g., EOC, certificate of coverage), contract terms, exclusions, limitations, and applicable state/federal requirements; deviations may lead to denial or non‑payment.
- Check evidence of coverage and contract terms for member-specific limitations
- State Medicaid provisions take precedence where they conflict with this policy
Clinical Background and Rationale
Intensity‑modulated radiotherapy (IMRT) is a technique that delivers highly conformal external beam radiation by modulating the intensity across one or more treatment fields, allowing differential dose levels within a target while sparing adjacent normal tissues. IMRT is particularly useful when targets are adjacent to critical structures or when simultaneous dose‑level customization within the target is required. The background literature cited in the policy highlights both clinical benefits (improved dose homogeneity and reduced acute toxicity in some settings) and practical considerations (planning/QA time and low‑dose exposure to larger normal volumes). Variants such as VMAT/OMRT are recognized as related, optimized modulated techniques and are standard approaches for many pediatric indications.
Definitions and Terminology
Policy Updates and Changes
Annual review: policy reorganized — removed I.B–G leaving I.A (Age ≤ 18 years) and added I.B (medically inoperable needing dose escalation), I.C (primary bone tumors), I.D (re‑irradiation where cumulative critical structure dose would exceed tolerance), and I.E.1–8 (enumerated site-specific indications); references reviewed and updated; specialist reviewed.
Annual review: removed several prescriptive breast dose‑volume subcriteria leaving homogeneity‑based breast criteria, revised left‑sided breast and APBI language, and added indications for esophageal cancer, mediastinal tumors, endometrial cancer, and select rectal cancer cases; references reviewed and updated.
Added note referring to MC.CP.MP.69 for Medicare criteria and specified 'non‑Medicare' health plans in Policy/Criteria I; annual review completed.
Annual review: background updated and references reviewed; ICD-10 code table removed.
Added thyroid and tonsils as head and neck subtypes; added cervical, vulvar, perianal indications per NCCN; updated background and coding (removed deleted CPT 0073T; added HCPCS G6016); specialist reviewed.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.